Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Uzma S. Asghar, Alexis R. Barr, Ros Cutts, Matthew Beaney, Irina Babina, Deepak Sampath, Jennifer Giltnane, Jennifer Arca Lacap, Lisa Crocker, Amy Young, Alex Pearson, Maria Teresa Herrera-Abreu, Chris Bakal, Nicholas C. Turner

Clin Cancer Res (2017) 23 (18): 5561–5572.

https://doi.org/10.1158/1078-0432.CCR-17-0369

Published: 14 September 2017

View article titled, Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models.

Claudia Iavarone, Ioannis Zervantonakis, Hsing-Yu Chen, Sangeetha S. Palakurthi, Joyce Fu Liu, Ursula A. Matulonis, Ronny I. Drapkin, Gordon B. Mills, Joel D. Leverson, Deepak Sampath, Joan S. Brugge

Clin Cancer Res (2016) 22 (2_Supplement): B48.

https://doi.org/10.1158/1557-3265.OVCA15-B48

Published: 15 January 2016

View article titled, Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models.

Journal Articles

Navitoclax enhances the activity of taxanes in non-small cell lung carcinoma (NSCLC) models

Nguyen Tan, Mehnaz Malek, Jiping Zha, Robert Kassees, Leanne Berry, Wayne J. Fairbrother, Deepak Sampath, Lisa Belmont

Clin Cancer Res (2010) 16 (19_Supplement): B24.

https://doi.org/10.1158/DIAG-10-B24

Published: 15 August 2014

View article titled, Navitoclax enhances the activity of taxanes in non-small cell lung carcinoma (NSCLC) models

Journal Articles

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Clin Cancer Res (2013) 19 (24): 6976–6986.

https://doi.org/10.1158/1078-0432.CCR-13-0978

Published: 16 December 2013

View article titled, Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Includes: Supplementary data

Journal Articles

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Clin Cancer Res (2013) 19 (7): 1760–1772.

https://doi.org/10.1158/1078-0432.CCR-12-3072

Published: 02 April 2013

View article titled, Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Includes: Supplementary data

Journal Articles

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Jill M. Spoerke, Carol O'Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner

Clin Cancer Res (2012) 18 (24): 6771–6783.

https://doi.org/10.1158/1078-0432.CCR-12-2347

Published: 16 December 2012

View article titled, Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Includes: Supplementary data

Journal Articles

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath

Clin Cancer Res (2012) 18 (14): 3901–3911.

https://doi.org/10.1158/1078-0432.CCR-11-2088

Published: 15 July 2012

View article titled, GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Includes: Supplementary data

Journal Articles

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

Nguyen Tan, Mehnaz Malek, Jiping Zha, Peng Yue, Robert Kassees, Leanne Berry, Wayne J. Fairbrother, Deepak Sampath, Lisa D. Belmont

Clin Cancer Res (2011) 17 (6): 1394–1404.

https://doi.org/10.1158/1078-0432.CCR-10-2353

Published: 15 March 2011

View article titled, Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

Includes: Supplementary data

Journal Articles

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O'Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner

Clin Cancer Res (2010) 16 (14): 3670–3683.

https://doi.org/10.1158/1078-0432.CCR-09-2828

Published: 14 July 2010

View article titled, Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Includes: Supplementary data

Journal Articles

Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models

Deepak Sampath, Lee M. Greenberger, Carl Beyer, Malathi Hari, Hao Liu, Michelle Baxter, Sharon Yang, Carol Rios, Carolyn Discafani

Clin Cancer Res (2006) 12 (11): 3459–3469.

https://doi.org/10.1158/1078-0432.CCR-05-2349

Published: 01 June 2006

View article titled, Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models

NARROW

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models.

Navitoclax enhances the activity of taxanes in non-small cell lung carcinoma (NSCLC) models

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only